Negative Impact of Anticardiolipid Antibodies on 1-Year Renal Allograft Estimated Glomerular Filtration Rate: A Cohort Study.
1Nephrology-Transplantation, APHP, Henri Mondor, Créteil, France
2Public Health, APHP, Henri Mondor, Créteil, France
3Immunology, APHP, Henri Mondor, Créteil, France
4Anatomopathology, APHP, Henri Mondor, Créteil, France.
Meeting: 2016 American Transplant Congress
Abstract number: A272
Keywords: Antibodies, Kidney
Session Information
Date: Saturday, June 11, 2016
Session Name: Poster Session A: Poster Session III: Kidney Complications-Other
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Halls C&D
In kidney transplant recipients, antiphospholipid positive tests without antiphospholipid syndrome (APS) were described up to 38% of patients and seem to be associated with thrombotic events. Kidney transplant outcomes and antiphospholipids have not been well described.
We conducted an observational, monocentric, retrospective study including 446 renal transplant recipients without APS, systemic lupus or primary coagulation abnormalities. Positivity anticardiolipin (ACL) threshold was 10 UI GPL (ELISA). Patients were screened before transplantation. ACL+ group was defined by at least one positive ACL detection.
ACL were screened in 247 patients. Among those, ACL- group included 101 patients (59%) and ACL+ group 146 (41%). Mean follow-up was 33.5 (16.6-36) months. Allografts and patients survival within 36 months were similar between both groups (graft losses: ACL+ N=15 (10%) vs. ACL- N=10 (10%) ; HR = 1.18). Thrombotic events did not differ between both groups (ACL+ N=20 (20%) vs. ACL- N=30 (21%); HR = 0.98). One year after transplant, eGFR was significantly lower in ACL+ group (48.5 (35.1-60.3) ml/min/1.73m2 vs. 51.9 (39.1-65.0) ml/min/1.73m2, p= 0.042). ACL was an independent risk factor of worst eGFR (p=0.03). Finally, we could not individualize chronic histological changes between implantation biopsies (ACL+ N=42 (42%); ACL- N=66 (45%)) and screening biopsies performed within three months (ACL+ N=50 (49%); ACL- N=68 (47%) and within 12 months after transplant (ACL+ N=52 (51%); ACL- N=76 (52%).
ACL without APS before kidney transplantation is an independent risk factor of eGFR decline within the first year post-transplant. Allografts, patients survival and thrombotic events were similar in both groups. Chronic histological changes within the first year after transplant were similar in both groups.
CITATION INFORMATION: Gauthier M, Canoui Poitrine F, Hue S, Desvaux D, Kofman T, Lang P, Grimbert P, Matignon M. Negative Impact of Anticardiolipid Antibodies on 1-Year Renal Allograft Estimated Glomerular Filtration Rate: A Cohort Study. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:
Gauthier M, Poitrine FCanoui, Hue S, Desvaux D, Kofman T, Lang P, Grimbert P, Matignon M. Negative Impact of Anticardiolipid Antibodies on 1-Year Renal Allograft Estimated Glomerular Filtration Rate: A Cohort Study. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/negative-impact-of-anticardiolipid-antibodies-on-1-year-renal-allograft-estimated-glomerular-filtration-rate-a-cohort-study/. Accessed January 18, 2021.« Back to 2016 American Transplant Congress